5 Indian CDMO Stocks Benefiting from the Global Pharma Outsourcing Boom

Synopsis: Global pharmaceutical companies are rapidly diversifying their manufacturing supply chains as geopolitical tensions, regulatory changes and the proposed U.S. BIOSECURE Act reduce dependence on China. With world-class manufacturing capabilities, USFDA-approved facilities and cost advantages, Indian Contract Development and Manufacturing Organisations (CDMOs) are emerging as major beneficiaries of this structural shift. Here are five Indian CDMO companies well positioned to capitalize on the growing global outsourcing opportunity.

The pharmaceutical industry has increasingly shifted toward the Contract Development and Manufacturing Organization (CDMO) model, where drug innovators outsource research, process development, clinical manufacturing and commercial production to specialized manufacturing partners. Instead of investing billions of dollars in manufacturing infrastructure, global pharmaceutical companies are increasingly partnering with CDMOs to accelerate drug development, reduce costs and improve operational flexibility.

India has become one of the world’s preferred outsourcing destinations due to its large pool of scientific talent, globally compliant manufacturing facilities and significantly lower production costs compared to developed markets. According to industry estimates, the Indian CDMO market is expected to reach around $26.7 billion by 2028, driven by rising biologics, specialty drugs, complex APIs and increasing outsourcing by multinational pharmaceutical companies.

The proposed U.S. BIOSECURE Act has further strengthened this long-term opportunity by encouraging pharmaceutical companies to diversify manufacturing away from China, creating additional growth prospects for Indian CDMO players.

1. Divi’s Laboratories

With a market capitalization of approximately Rs. 1,81,328.31 crore, Divi’s Laboratories remains India’s largest and most established CDMO and Active Pharmaceutical Ingredient (API) manufacturer. The stock was trading near Rs. 6,830 on the NSE.

The company is widely regarded as one of the biggest beneficiaries of global pharma outsourcing due to its leadership in custom synthesis, complex APIs and long-standing relationships with multinational pharmaceutical companies. During FY26, Divi’s reported revenue of Rs. 10,560 crore, with nearly 89 percent of its revenue generated from exports.

Its newly commissioned Kakinada Unit III, FY26 capital expenditure of Rs. 1,544 crore, expansion into GLP-1 molecules and completely debt-free balance sheet position the company strongly to capture rising outsourcing demand from global innovators seeking reliable alternatives to China.

2. Syngene International

With a market capitalization of approximately Rs. 17,050.98 crore, Syngene International was trading near Rs. 422.40 per share. Syngene operates one of India’s most integrated Contract Research, Development and Manufacturing (CRDMO) platforms, serving over 400 global customers across drug discovery, development, clinical research and commercial manufacturing.

The company reported FY26 revenue of Rs. 3,739 crore, while maintaining an EBITDA margin of around 25 percent. Strategic investments in antibody-drug conjugates (ADCs), peptides, biologics and advanced manufacturing, along with the extension of its long-term partnership with Bristol Myers Squibb until 2035, provide strong long-term revenue visibility.

As global pharmaceutical companies increasingly outsource research-intensive and high-value manufacturing activities, Syngene is well positioned to benefit from this structural industry shift.

3. Cohance Lifesciences Ltd 

With a market capitalization of approximately Rs. 17,288.21 crore, the shares of Cohance Lifesciences Ltd were trading near Rs. 451.90 apiece. The company specializes in high-margin innovator CDMO services, working closely with global pharmaceutical companies on patented drug molecules rather than generic products. Following the merger of Suven Pharmaceuticals and Cohance Lifesciences, the combined entity has created an integrated platform spanning drug discovery, development, and commercial manufacturing.

The company is expected to maintain industry-leading EBITDA margins of 42–45 percent while expanding manufacturing capacity at its Pashamylaram facility. With expertise in complex CNS chemistry and intellectual property-sensitive projects, Cohance Lifesciences is well positioned to benefit as multinational pharmaceutical companies increasingly diversify their outsourcing strategies beyond China, driving long-term growth opportunities for the CDMO business.

4. Piramal Pharma

With a market capitalization of approximately Rs. 23,524.92 crore, Piramal Pharma was trading near Rs. 176.70 per share. Piramal Pharma possesses one of the most diversified global manufacturing footprints among Indian CDMO companies, with facilities across the United States, United Kingdom, Canada and India. This international presence provides multinational customers with greater supply chain flexibility under evolving geopolitical and regulatory conditions.

Although FY26 remained a transition year, the company reported CDMO revenue of Rs. 4,915 crore while witnessing a 75 percent year-on-year increase in U.S. biopharma funding during the second half of FY26. Investments in antibody-drug conjugates, high-potency APIs, sterile injectables and biologics manufacturing position Piramal to capture higher outsourcing demand over the coming years.

5. Gland Pharma

With a market capitalization of approximately Rs. 40,827.52 crore, Gland Pharma was trading near Rs. 2,475 per share. Gland Pharma has built a strong competitive advantage in sterile injectable manufacturing—one of the pharmaceutical industry’s most technically demanding and highly regulated segments. Operating under a pure B2B model, the company manufactures injectable products exclusively for global pharmaceutical companies without competing through its own branded portfolio.

Its acquisition of Cenexi has expanded manufacturing capabilities into France and Belgium, strengthening its presence across Europe while adding biologics fill-and-finish and advanced injectable capabilities. Supported by multiple USFDA-approved facilities and expectations of nearly 20 percent PAT CAGR through FY28, Gland Pharma remains well positioned to benefit from the ongoing shift in global pharmaceutical outsourcing.

Why CDMO Companies Matter

Unlike traditional pharmaceutical companies that rely on launching their own medicines, CDMOs generate revenue by providing research, development, manufacturing and commercialization services to global drug innovators. This business model typically offers long-term customer relationships, high regulatory entry barriers, stable cash flows and strong operating leverage.

As pharmaceutical companies continue diversifying manufacturing beyond China while focusing on reducing capital expenditure, India’s CDMO industry is expected to witness sustained long-term growth. Companies with proven regulatory compliance, complex chemistry capabilities and global manufacturing footprints are likely to emerge as key beneficiaries of this structural transformation in the global pharmaceutical supply chain.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses arising from decisions based on this article. Please consult your investment advisor before investing.

The post 5 Indian CDMO Stocks Benefiting from the Global Pharma Outsourcing Boom appeared first on Trade Brains.